Pay to Marwadi

Company Profile

SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

NSE : SPARCBSE : 532872ISIN CODE : INE232I01014Industry : Business SupportHouse : Sun Pharma
BSE225.60-11.85 (-4.99 % )
PREV CLOSE (Rs.) 237.45
OPEN PRICE (Rs.) 239.35
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 227135
TODAY'S LOW / HIGH (Rs.)225.60 239.40
52 WK LOW / HIGH (Rs.)178.1 474
NSE225.50 -11.85 (-4.99 % )
PREV CLOSE(Rs.) 237.35
OPEN PRICE (Rs.) 238.55
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 225.50 (92248 )
VOLUME 2436000
TODAY'S LOW / HIGH(Rs.) 225.50 239.50
52 WK LOW / HIGH (Rs.)178.8 472.8

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.00
TTM EPS (Rs.) -11.20
P/E Ratio 0.00
Book Value (Rs.) 7.15
Face Value (Rs.) 1
MCap (Rs. in Mn) 73212.07
Price/Earning (TTM) -20.86
Price/Sales (TTM) 68.63
Price/Book (MRQ) 31.55
PAT Margin (%) -93.22
ROCE (%) -69.44
Incorporation Year : 2006

Management Info :

Dilip S Shanghvi - Chairman - Managing Director

Registered Office :

Address : Plot No.5 & 6/1, Savli G. I. D. C. Estate,Savli - Vadodara Highway,Manjusar ,
Vadodara,
Gujarat-391775

Phone : 0265- 2330815

Website : www.sparc.life

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
10Apr04-10-2024$Sun Pharma Advanced Research Company informs about compliance certificate Sun Pharma Advanced Research
Sun Pharma Advanced Research Company has confirmed that activities in relation to share transfer facility were duly maintained by the Company's Registrar and Share Transfer Agent, Link lntime India (a SEBI registered Category-I Registrar & Share Transfer Agent with Registration Number: INR000004058) during the financial year ended March 31, 2024.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Advanced Research Company has confirmed that activit..
10Apr04-10-2024$Sun Pharma Advanced Research Company informs about press release Sun Pharma Advanced Research

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company that it enclosed the Press Release titled ‘SPARC Announces Results from the Planned Interim Analysis of the PROSEEK Study of Vodobatinib in Patients with Early Parkinson’s Disease’, which the company will be releasing after sending this letter.

The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and..
07Mar03-07-2024$Sun Pharma Advanced Research Company informs about loss of share certificates Sun Pharma Advanced Research
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company has informed that it enclosed the details of loss of share certificates/request for issue of duplicate share certificate reported by shareholder(s) of the Company, received from its Registrar and Transfer Agent, Link Intime India on March 06, 2024.

The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations a..
04Jan01-04-2024$Sun Pharma Advanced Research Company informs about clarification on price movement Sun Pharma Advanced Research
Sun Pharma Advanced Research Company has confirmed that the Company is in compliance with the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and that all the disclosures required to be made under the said regulation have been made to the exchanges. They are not aware of any information which qualifies to be disclosed under the said regulation. They remain committed to make adequate and timely disclosures to the Stock Exchanges in compliance with the applicable regulations.

The above information is a part of company’s filings submitted to BSE.
Sun Pharma Advanced Research Company has confirmed that the Com..
06Nov11-06-2023$Sun Pharma Advanced Research Company informs about statement on deviation or variation Sun Pharma Advanced Research

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, Sun Pharma Advanced Research Company has confirmed that there is no deviation or variation in the use of proceeds, from the objects stated in the explanatory statement to the resolution contained in the Notice dated May 12, 2021 of the extra-ordinary general meeting of the Company and /or the Private Placement Offer cum Application Letter dated June 08, 2021 for the Preferential Issue of the Company. A statement confirming that there is no deviation or variation in the utilisation of these proceeds, duly reviewed and approved by the Audit Committee at its meeting held today November 06, 2023, is enclosed.

The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 32 of the SEBI (Listing Obligations and..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit-996.5-2225.8
Gross Profit -996.5 -2225.8
Operating Profit -962.3-2031.8
Net Sales 138.62387.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Krystal Integrated (BSE)
 756.55 (3.60%)
M.Cap ( in Cr)
1057.05
Techknowgreen Solutn (BSE)
 241.20 (7.20%)
M.Cap ( in Cr)
178.07
Swadeshi Polytex (BSE)
 267.10 (4.99%)
M.Cap ( in Cr)
1041.69
Medi Assist Health (BSE)
 510.30 (0.72%)
M.Cap ( in Cr)
3582.78
Vanta Bioscience (BSE)
 75.20 (4.94%)
M.Cap ( in Cr)
47.47
Shareholding Pattern More
PROMOTERS 65.67 %
NON-INSTITUTION 30.42 %
MUTUAL FUNDS/UTI 0.25 %
FI/BANKS/INSURANCE 0 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes